Cytokinetics, Incorporated

CYTK

CIK 0001061983 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$18M
↑+4.9% +$828Kvs FY2024 (Q4)
Gross Profit
$18M
↑+4.9% +$828Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
72/100
  • Profitability
    100ROIC 212.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.53 (above 1.5 = solid)
  • Leverage
    100D/E -0.37 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.06x (1.0+ = capital-efficient)
  • Growth
    33Revenue YoY +4.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -8613.4% · trend +26389.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$25M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$112M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.42B
everything owned
Total liabilities
$2.08B
everything owed
Stockholders' equity
$-660M
shareholder claim
Net debt
$124M
LT debt minus cash

Recent performance · 63 quarters

Revenue↑+4.9% +$828K
$18M
Net Income↓-90.7% -$146M
$-306M
Free Cash Flow↓-337.5% -$4M
$-6M
Operating Margin↑+21797.2pts
-8613.4%

Drill down